Barclays 28th Annual Global Healthcare Conference March 10, 2026 9:30 AM EDTCompany ParticipantsLavina Talukdar - Senior VP & ...
The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.
The Food and Drug Administration’s embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he’s departed after controversial ...
Dr. Vinay Prasad, a polarizing figure at the Food and Drug Administration who oversaw vaccines, is leaving the agency at the end of April, according to a Health and Human Services spokesperson. As the ...
The Bulwark on MSNOpinion
FDA reverses course, agrees to review Moderna’s flu vaccine
Andrew Egger and Jonathan Cohn give their takes on the stunning back-and-forth at the FDA over Moderna’s new mRNA flu vaccine ...
Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.
Explore how Moderna makes money through its mRNA vaccines, government contracts, and partnerships, and how products like its COVID-19 vaccine drive revenue.
Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.
But just a week later, on Feb. 18, the FDA backtracked on its decision, saying that it will indeed review the vaccine, potentially in time for its approval for the ...
Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results